The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women
Abstract
Androgens have important physiological effects in women. Postmenopausal androgen replacement, most commonly as testosterone therapy, is becoming increasingly widespread. This is despite the lack of clear guidelines regarding the diagnosis of androgen insufficiency, optimal therapeutic doses, and long-term safety data. With respect to the breast specifically, there is the potential for exogenous testosterone to exert either androgenic or indirect estrogenic actions, with the latter potentially increasing breast cancer risk. In experimental studies, androgens exhibit growth-inhibitory and apoptotic effects in some, but not all, breast cancer cell lines. Differing effects between cell lines appear to be due primarily to variations in concentrations of specific coregulatory proteins at the receptor level. In rodent breast cancer models, androgen action is antiproliferative and proapoptotic, and is mediated via the androgen receptor, despite the potential for testosterone and dehydroepiandrosterone to be aromatized to estrogen. The results from studies in rhesus monkeys suggest that testosterone may serve as a natural endogenous protector of the breast and limit mitogenic and cancer-promoting effects of estrogen on mammary epithelium. Epidemiological studies have significant methodological limitations and provide inconclusive results. The strongest data for exogenous testosterone therapy comes from primate studies. Based on such simulations, inclusion of testosterone in postmenopausal estrogen-progestin regimens has the potential to ameliorate the stimulating effects of combined estrogen-progestin on the breast. Research addressing this is warranted; however, the number of women that would be required for an adequately powered randomized controlled trial renders such a study unlikely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
DUNN, J. F., NISULA, B. C., & RODBARD, D. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-1-58 · Cited by 1,238 · cited 11×
“SHBG is a pivotal determinant of the bioavailability of sex steroids, and variations in the plasma levels of SHBG impact significantly on the amount of free and other bound sex steroids (20).”
BackgroundInfluentialTransdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.4.328 · Cited by 877
Burger, H. G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02985-0 · Cited by 771 · cited 1×
“DHT is a nonaromatizable androgen (16, 17) (Fig.”
BackgroundLabrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · cited 10×
“cline with increasing age in women before menopause (2, 3),”
BackgroundInfluentialJUDD, H. L., JUDD, G. E., LUCAS, W. E., & YEN, S. S. C. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-6-1020 · Cited by 511
Zumoff, B., Strain, G. W., Miller, L. K., & Rosner, W. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.4.7714119 · Cited by 392 · cited 2×
“cline with increasing age in women before menopause (2, 3),”
BackgroundLabrie, F., Luu-The, V, Lin, S., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., & Belanger, A. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250001 · Cited by 278
Judd, H. L., Lucas, W. E., & Yen, S. S. C. (1974) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(74)90490-6 · Cited by 261
Cited by
Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen
Davis, S. R., Moreau, M., Kroll, R., Bouchard, C., Panay, N., Gass, M., Braunstein, G. D., Hirschberg, A. L., Rodenberg, C., Pack, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707302 · Cited by 479
Self-citationAndrogen therapy in women: a reappraisal: an Endocrine Society Clinical Practice Guideline
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2260 · Cited by 363
Self-citationHlisníková, H., Petrovičová, I., Kolena, B., Šidlovská, M., & Sirotkin, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17186811 · Cited by 331
Androgen therapy in women: An Endocrine Society clinical practice guideline
Wierman, M. E., Basson, R., Davis, S. R., Khosla, S., Miller, K. K., Rosner, W., & Santoro, N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1121 · Cited by 301
Self-citationDarbre, P. D. (2006) · Journal of Applied Toxicology · doi:10.1002/jat.1135 · Cited by 295
Testosterone in women—the clinical significance
Davis, S. R., & Wahlin-Jacobsen, S. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00284-3 · Cited by 290
Self-citationMinireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?
Hickey, T. E., Robinson, J. L. L., Carroll, J. S., & Tilley, W. D. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1107 · Cited by 289
Advances in Platinum Chemotherapeutics
Harper, B. W., Krause‐Heuer, A. M., Grant, M. P., Manohar, M., Garbutcheon‐Singh, K. B., & Aldrich‐Wright, J. R. (2010) · Chemistry – A European Journal · doi:10.1002/chem.201000148 · Cited by 267
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., Jindal, S., Hui, M., Finlay-Schultz, J., Ebrahimie, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01168-7 · Cited by 257
Davis, S. R., van der Mooren, M. J., van Lunsen, R. H. W., Lopes, P., Ribot, J., Rees, M., Moufarege, A., Rodenberg, C., Buch, A., & Purdie, D. W. (2006) · Menopause · doi:10.1097/01.gme.0000179049.08371.c7 · Cited by 250
Self-citationWalters, K. A., Simanainen, U., & Handelsman, D. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq003 · Cited by 183
Sex steroid-producing enzymes in human breast cancer
Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., & Sasano, H. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00834 · Cited by 182
Wang, T., Sha, L., Li, Y., Zhu, L., Wang, Z., Li, K., Lu, H., Bao, T., Guo, L., Zhang, X., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00284 · Cited by 162
Ito, K., Miki, Y., Suzuki, T., McNamara, K. M., & Sasano, H. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0470 · Cited by 29
Sirianni, R., Capparelli, C., Chimento, A., Panza, S., Catalano, S., Lanzino, M., Pezzi, V., & Andò, S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.002 · Cited by 25
“Emerging evidence indicate that androgens mainly exert inhibitory effects on the growth of normal mammary epithelial cells and play a protective role in the pathogenesis of breast cancer (Labrie et al., 2003; Somboonporn and Davis, 2004; Tworoger et al., 2005; Yeh et al., 2003).”
Metadata
- Authors
- Somboonporn, W., & Davis, S. R.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2004-06-01
- Volume
- 25
- Issue
- 3
- Pages
- 374-388
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2169698993
- Cited by
- 214
- References
- 21
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.